Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
901 to 920 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression. | Front Oncol | 2021 | 34041018 | PubTator, text mining | PubMed |
| An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib. | Leuk Res Rep | 2021 | 34040960 | PubTator, text mining | PubMed |
| T-bet+CD27+CD21- B cells poised for plasma cell differentiation during antibody-mediated rejection of kidney transplants. | JCI Insight | 2021 | 34032636 | PubTator, text mining | PubMed |
| Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy. | Curr Hematol Malig Rep | 2021 | 34021874 | PubTator, text mining | PubMed |
| The balance between the intronic miR-342 and its host gene Evl determines hematopoietic cell fate decision. | Leukemia | 2021 | 34021250 | PubTator, text mining | PubMed |
| Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. | Ann Hematol | 2021 | 34018029 | PubTator, text mining | PubMed |
| Global characterization of B cell receptor repertoire in COVID-19 patients by single-cell V(D)J sequencing. | Brief Bioinform | 2021 | 34015809 | PubTator, text mining | PubMed |
| Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. | Leukemia | 2021 | 34007049 | PubTator, text mining | PubMed |
| Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. | Nat Commun | 2021 | 34001881 | PubTator, text mining | PubMed |
| SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis. | Blood Cancer J | 2021 | 34001853 | PubTator, text mining | PubMed |
| The Predominant Prognostic Significance of NOTCH1 Mutation Defined by Emulsion PCR in Chronic Lymphocytic Leukemia. | Cancer Manag Res | 2021 | 33986614 | PubTator, text mining | PubMed |
| A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation. | Nat Commun | 2021 | 33976229 | PubTator, text mining | PubMed |
| A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. | Nat Commun | 2021 | 33976198 | PubTator, text mining | PubMed |
| Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. | Br J Haematol | 2021 | 33973230 | PubTator, text mining | PubMed |
| Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. | Blood Cancer J | 2021 | 33972504 | PubTator, text mining | PubMed |
| Discovery of Candidate DNA Methylation Cancer Driver Genes. | Cancer Discov | 2021 | 33972312 | PubTator, text mining | PubMed |
| Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib. | Clin Cancer Res | 2021 | 33963002 | PubTator, text mining | PubMed |
| Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes. | PLoS Biol | 2021 | 33961621 | PubTator, text mining | PubMed |
| Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options. | Blood | 2021 | 33945616 | PubTator, text mining | PubMed |
| Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL. | MAbs | 2021 | 33944659 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=46